Must-See Earnings Estimates NYSE:TPB, NYSE:RWT, NYSE:KMPR, NASDAQ:IRMD

0
40

TURNING POINT BRANDS EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NYSE:TPB)

Turning Point Brands last posted its quarterly earnings data on October 25th, 2021. The reported $0.72 EPS for the quarter, beating the consensus estimate of $0.70 by $0.02. The business earned $109.90 million during the quarter, compared to analysts’ expectations of $112.93 million. Its revenue for the quarter was up 5.5% compared to the same quarter last year. Turning Point Brands has generated $2.81 earnings per share over the last year ($2.35 diluted earnings per share) and currently has a price-to-earnings ratio of 16.2. Earnings for Turning Point Brands are expected to grow by 15.57% in the coming year, from $2.89 to $3.34 per share. Turning Point Brands has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, February 9th, 2022 based off prior year’s report dates.

IS TURNING POINT BRANDS A BUY RIGHT NOW? (NYSE:TPB)

3 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Turning Point Brands in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” Turning Point Brands stock.
Turning Point Brands

REDWOOD TRUST EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NYSE:RWT)

Redwood Trust last issued its quarterly earnings results on October 27th, 2021. The real estate investment trust reported $0.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.39. Redwood Trust has generated $0.04 earnings per share over the last year ($2.82 diluted earnings per share) and currently has a price-to-earnings ratio of 4.8. Earnings for Redwood Trust are expected to decrease by -3.88% in the coming year, from $1.29 to $1.24 per share. Redwood Trust has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, February 9th, 2022 based off prior year’s report dates.

IS REDWOOD TRUST A BUY RIGHT NOW? (NYSE:RWT)

7 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Redwood Trust in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should “buy” Redwood Trust stock.
Redwood Trust

KEMPER EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NYSE:KMPR)

Kemper last issued its earnings data on October 28th, 2021. The insurance provider reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by $1.12. The company had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.47 billion. Its quarterly revenue was up 7.5% compared to the same quarter last year. Kemper has generated $6.57 earnings per share over the last year ($4.17 diluted earnings per share) and currently has a price-to-earnings ratio of 15.2. Earnings for Kemper are expected to grow by 332.76% in the coming year, from $1.16 to $5.02 per share. Kemper has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, February 7th, 2022 based off prior year’s report dates.

IS KEMPER A BUY RIGHT NOW? (NYSE:KMPR)

1 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Kemper in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should “buy” Kemper stock.
Kemper

IRADIMED EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NASDAQ:IRMD)

IRadimed last released its quarterly earnings results on July 29th, 2021. The medical equipment provider reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.04. The business had revenue of $9.81 million for the quarter, compared to analyst estimates of $9.58 million. IRadimed has generated $0.11 earnings per share over the last year ($0.37 diluted earnings per share) and currently has a price-to-earnings ratio of 100.9. Earnings for IRadimed are expected to grow by 33.96% in the coming year, from $0.53 to $0.71 per share.

IS IRADIMED A BUY RIGHT NOW? (NASDAQ:IRMD)

1 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for IRadimed in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” IRadimed stock.
IRadimed